The Daubert hearing on general causation in MDL 3140, In re: Depo-Provera (Depot Medroxyprogesterone Acetate) Products Liability Litigation, opens Tuesday, June 24, 2026 before Judge M. Casey Rodgers in the Northern District of Florida and runs through Thursday. Both sides have completed expert depositions, exchanged briefing, and reduced their causation theories to whichever opinions Judge Rodgers will let a jury hear. The ruling will set the trajectory of more than 3,400 federally consolidated meningioma claims and a growing inventory of state-court filings, and it will shape settlement posture going into the December 7 Blonski v. Pfizer bellwether.
What the Hearing Tests
The narrow legal question is whether plaintiffs' general causation experts can reliably opine that medroxyprogesterone acetate, the active ingredient in Pfizer's Depo-Provera contraceptive injection, causes intracranial meningioma. Pfizer's five experts will face the same scrutiny in reverse, with plaintiffs arguing that the defense theories rest on selective epidemiology and discount the biological mechanism for progesterone-driven meningioma growth.
Plaintiffs' lead epidemiology evidence is the March 2024 BMJ study by Roland and colleagues that reported a meaningfully elevated meningioma risk among long-term users of injectable medroxyprogesterone acetate, with the strongest signal concentrated in patients exposed for at least one year. Pfizer's experts attack the study on confounding and selection grounds and rely on older U.S. observational literature that did not detect a similar association. Judge Rodgers will not be deciding which side is right. She will be deciding whether plaintiffs' methodology satisfies Rule 702 and the post-2023 amendment standard, which tightened the gatekeeping role and explicitly placed the burden on the proponent.
The Preemption Overlay
Pfizer's federal preemption defense, fully briefed and pending on a parallel track, was the more existential threat to the litigation a year ago. The FDA's December 2025 label change that added an express intracranial meningioma warning to Depo-Provera substantially narrowed the defense. Plaintiffs whose exposure ended before the label change can credibly argue that newly acquired information under 21 C.F.R. 314.70(c)(6)(iii)(A) permitted Pfizer to strengthen the warning unilaterally years earlier, taking the case outside the impossibility-preemption framework set by Wyeth v. Levine and tightened by Merck Sharp and Dohme v. Albrecht.
The FDA labeling change does not make the preemption motion moot, because Pfizer continues to argue that the agency rejected earlier proposed language and that the timing of available scientific evidence supports its position. But the defense lost its cleanest version of the argument when the FDA itself adopted the warning plaintiffs say should have been there for years.
Bellwether Selection and What It Signals
Judge Rodgers selected five bellwether trial plaintiffs in spring 2026, with Blonski v. Pfizer set for December 7. The selection criteria favored cases with documented long-term Depo-Provera exposure, biopsy-confirmed meningioma, and exposure histories that predate the December 2025 label change. That mix lets both sides test their strongest causation arguments without the noise of short-exposure outliers or post-warning cases that drag preemption back to center stage.
For practitioners with cases in the inventory or considering intake, three signals from the bellwether structure matter.
- Duration of exposure is the case-selection filter. MDL leadership is treating roughly one year of cumulative exposure as the threshold for a viable file, consistent with the Roland study's dose-response findings. Shorter-exposure cases will need additional support to survive Daubert at the individual level.
- Diagnosis timing matters. Cases where the meningioma diagnosis predates the December 2025 label change present cleaner failure-to-warn claims than cases diagnosed under the updated label. The latter group will face a stronger learned-intermediary defense.
- State-court parallel tracks are growing. California, New Jersey, and Pennsylvania state filings have accelerated since the FDA labeling action. Practitioners weighing forum should track Judge Rodgers' Daubert ruling closely; an adverse ruling pushes more inventory to state court, where Frye jurisdictions and individual-state Daubert variants may give a different answer on the same experts.
What a Bad Ruling Looks Like for Plaintiffs
The worst-case outcome for plaintiffs is a partial Daubert exclusion that leaves the mechanism evidence in but cuts the epidemiology, or that limits experts to opining about high-dose long-term exposure only. That outcome would not end the litigation. It would compress the viable case population, depress settlement values, and force MDL leadership to retool the bellwether pool. A full-exclusion outcome is unlikely given the BMJ publication and the FDA's own adoption of the warning, but defense counsel will press for the most restrictive admissibility ruling Judge Rodgers will sign.
A clean plaintiff win at Daubert, by contrast, is the inflection point that typically triggers settlement discussions in pharmaceutical MDLs. Pfizer's appetite for trying Blonski drops sharply if the company faces the Roland epidemiology, the FDA's late warning, and a sympathetic product-liability plaintiff in the Northern District of Florida.
Practice Notes for the Inventory
For firms carrying Depo-Provera cases, three operational items deserve attention this week.
Pull updated prescriber records
Cumulative exposure documentation is the first thing defense counsel will challenge at the individual level. Get pharmacy fill histories, prescriber notes, and any patient-reported exposure logs into the file now. Gaps surface in deposition, and they are easier to close before the prescriber is deposed than after.
Document the diagnostic pathway
Biopsy reports, imaging studies, and any neurosurgery operative notes anchor the diagnosis. For cases without biopsy confirmation, the imaging characterization needs to support meningioma rather than other intracranial lesions. Med-mal counsel in the same firm can usually pull these records faster than products teams working cold.
Calendar the December bellwether
Blonski v. Pfizer's December 7 trial date is the next inflection point after Daubert. Settlement discussions in product-liability MDLs typically open in the window between a favorable Daubert ruling and the first bellwether verdict. Inventory firms should be prepared to staff demand packages, lien-resolution workflows, and client communications for a fast-moving fall.
The Bottom Line
The June 24 hearing is the most consequential procedural event in MDL 3140 to date. A plaintiff win on general causation, combined with the FDA's December 2025 label change, sets up a December bellwether with substantially better facts than Pfizer would have faced a year ago. A partial exclusion narrows but does not extinguish the litigation. Either way, the window for low-friction intake is closing as Daubert clarifies which exposure profiles will move at scale.